BACKGROUND: Characterizing neuropsychological (NP) functioning of individuals at clinical high risk (CHR) for psychosis may be useful for prediction of psychosis and understanding functional outcome. The degree to which NP impairments are associated with general cognitive ability and/or later emergence of full psychosis in CHR samples requires study with well-matched controls. METHODS: We assessed NP functioning across eight cognitive domains in a sample of 73 CHR youth, 13 of whom developed psychotic-level symptoms after baseline assessment, and 34 healthy comparison (HC) subjects. Groups were matched on age, sex, ethnicity, handedness, subject and parent grade attainment, and median family income, and were comparable on WRAT-3 Reading, an estimate of premorbid IQ. Profile analysis was used to examine group differences and the role of IQ in profile shape. RESULTS: The CHR sample demonstrated a significant difference in overall magnitude of NP impairment but only a small and nearly significant difference in profile shape, primarily due to a large impairment in olfactory identification. Individuals who subsequently developed psychotic-level symptoms demonstrated large impairments in verbal IQ, verbal memory and olfactory identification comparable in magnitude to first episode samples. CONCLUSIONS: CHR status may be associated with moderate generalized cognitive impairments marked by some degree of selective impairment in olfaction and verbal memory. Impairments were greatest in those who later developed psychotic symptoms. Future study of olfaction in CHR samples may enhance early detection and specification of neurodevelopmental mechanisms of risk.
BACKGROUND: Characterizing neuropsychological (NP) functioning of individuals at clinical high risk (CHR) for psychosis may be useful for prediction of psychosis and understanding functional outcome. The degree to which NP impairments are associated with general cognitive ability and/or later emergence of full psychosis in CHR samples requires study with well-matched controls. METHODS: We assessed NP functioning across eight cognitive domains in a sample of 73 CHR youth, 13 of whom developed psychotic-level symptoms after baseline assessment, and 34 healthy comparison (HC) subjects. Groups were matched on age, sex, ethnicity, handedness, subject and parent grade attainment, and median family income, and were comparable on WRAT-3 Reading, an estimate of premorbid IQ. Profile analysis was used to examine group differences and the role of IQ in profile shape. RESULTS: The CHR sample demonstrated a significant difference in overall magnitude of NP impairment but only a small and nearly significant difference in profile shape, primarily due to a large impairment in olfactory identification. Individuals who subsequently developed psychotic-level symptoms demonstrated large impairments in verbal IQ, verbal memory and olfactory identification comparable in magnitude to first episode samples. CONCLUSIONS: CHR status may be associated with moderate generalized cognitive impairments marked by some degree of selective impairment in olfaction and verbal memory. Impairments were greatest in those who later developed psychotic symptoms. Future study of olfaction in CHR samples may enhance early detection and specification of neurodevelopmental mechanisms of risk.
Authors: Shona M Francey; Henry J Jackson; Lisa J Phillips; Stephen J Wood; Alison R Yung; Patrick D McGorry Journal: Schizophr Res Date: 2005-11-01 Impact factor: 4.939
Authors: Keith H Nuechterlein; Deanna M Barch; James M Gold; Terry E Goldberg; Michael F Green; Robert K Heaton Journal: Schizophr Res Date: 2004-12-15 Impact factor: 4.939
Authors: Warrick J Brewer; Shona M Francey; Stephen J Wood; Henry J Jackson; Christos Pantelis; Lisa J Phillips; Alison R Yung; Vicki A Anderson; Patrick D McGorry Journal: Am J Psychiatry Date: 2005-01 Impact factor: 18.112
Authors: Vidyulata Kamath; Bruce I Turetsky; Monica E Calkins; Christian G Kohler; Catherine G Conroy; Karin Borgmann-Winter; Dana E Gatto; Raquel E Gur; Paul J Moberg Journal: World J Biol Psychiatry Date: 2011-11-10 Impact factor: 4.132
Authors: Bruce I Turetsky; Vidyulata Kamath; Monica E Calkins; Warrick J Brewer; Stephen J Wood; Christos Pantelis; Larry J Seidman; Dolores Malaspina; Kimberley P Good; Lili C Kopala; Paul J Moberg Journal: Schizophr Res Date: 2012-05-14 Impact factor: 4.939
Authors: Barnaby Nelson; G Paul Amminger; Hok Pan Yuen; Nicky Wallis; Melissa J Kerr; Lisa Dixon; Cameron Carter; Rachel Loewy; Tara A Niendam; Martha Shumway; Sarah Morris; Julie Blasioli; Patrick D McGorry Journal: Early Interv Psychiatry Date: 2017-07-18 Impact factor: 2.732
Authors: Vidyulata Kamath; Paul J Moberg; Monica E Calkins; Karin Borgmann-Winter; Catherine G Conroy; Raquel E Gur; Christian G Kohler; Bruce I Turetsky Journal: Schizophr Res Date: 2012-04-25 Impact factor: 4.939
Authors: Kelly Elizabeth Gill; Elizabeth Evans; Jürgen Kayser; Shelly Ben-David; Julie Messinger; Gerard Bruder; Dolores Malaspina; Cheryl Mary Corcoran Journal: Psychiatry Res Date: 2014-07-17 Impact factor: 3.222
Authors: Nikolaos Koutsouleris; Christos Davatzikos; Ronald Bottlender; Katja Patschurek-Kliche; Johanna Scheuerecker; Petra Decker; Christian Gaser; Hans-Jürgen Möller; Eva M Meisenzahl Journal: Schizophr Bull Date: 2011-05-16 Impact factor: 9.306
Authors: Kristen A Woodberry; William R McFarlane; Anthony J Giuliano; Mary B Verdi; William L Cook; Stephen V Faraone; Larry J Seidman Journal: Schizophr Res Date: 2013-02-22 Impact factor: 4.939
Authors: Vidyulata Kamath; Bruce I Turetsky; Sarah C Seligman; Dana M Marchetto; Jeffrey B Walker; Paul J Moberg Journal: Arch Clin Neuropsychol Date: 2013-03-28 Impact factor: 2.813